16 patents
Utility
Use of Tapinarof for the Treatment of Atopic Dermatitis
28 Dec 23
Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein.
John E. KRAUS, James LEE
Filed: 1 Sep 23
Utility
Topical Pharmaceutical Compositions
20 Jul 23
The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase.
Piyush JAIN, Robert Michael LEMING, Glenn TABOLT, Alan Scott COLBORN
Filed: 24 Jun 21
Utility
Cationic Lipids for Lipid Nanoparticle Delivery of Therapeutics to Hepatic Stellate Cells
18 May 23
Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.
James HEYES, Kieu Mong Lam, Richard J. Holland
Filed: 12 Mar 21
Utility
Cationic Lipids for Lipid Nanoparticle Delivery of Therapeutics to Hepatic Stellate Cells
4 May 23
Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.
James HEYES, Kieu Mong LAM, Richard J. HOLLAND, Wenxuan ZHANG
Filed: 11 Feb 21
Utility
Topical Pharmaceutical Compositions
27 Apr 23
The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase.
Sujatha D. SONTI, Joey Roger THOMAS, Jon LENN, Leandro SANTOS, Justin WHITEMAN, Michael Quinn DOHERTY, Mary BEDARD, Piyush JAIN
Filed: 15 Dec 22
Utility
ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE
20 Apr 23
The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof.
Channa K. JAYAWICKREME, Susan H. SMITH, Cunyu ZHANG, William ZUERCHER
Filed: 28 Oct 22
Utility
Use of Tapinarof for the Treatment of Chronic Plaque Psoriasis
6 Apr 23
Topical compositions and methods for using topical compositions comprising tapinarof to treat chronic mild to moderate plaque psoriasis are described herein.
John E. KRAUS, James LEE
Filed: 2 May 22
Utility
Methods, Compositions, and Systems for Delivering Therapeutic and Diagnostic Agents into Cells
9 Feb 23
Disclosed are methods for delivering a therapeutic or diagnostic agent to the cytosol of a cell in a subject.
Mary G. PRIEVE, Michael E. HOUSTON, JR., Pierrot HARVIE, Sean D. MONAHAN
Filed: 7 Jan 22
Utility
Ornithine Transcarbamylase (Otc) Constructs and Methods of Using the Same
5 Jan 23
The present disclosure provides, among other things, polynucleotide constructs, compositions, and methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need thereof a composition comprising a polynucleotide construct comprising a 5′ UTR, a codon optimized mRNA encoding an ornithine transcarbamylase, and a 3′ UTR.
Owen DALY, Kieu LAM, James HEYES, Richard HOLLAND, Christine ESAU, Ed YAWORSKI, Mary PRIEVE
Filed: 22 Oct 20
Utility
Remittive Effects of Tapinarof In the Treatment of Plaque Psoriasis, Atopic Dermatitis, or Radiation Dermatitis
15 Dec 22
Embodiments described herein are directed to methods for treating moderate to severe plaque psoriasis, atopic dermatitis, or radiation dermatitis in a subject comprising administering about 1.0% tapinarof in a topical composition to the affected areas of the subject once a day for an initial period of time until the plaque psoriasis, atopic dermatitis, or radiation dermatitis is clear at which time the administration is stopped, and reassessing the subject from about 3 months to about 12 months after administration is stopped to determine if further treatment is required.
David Scott RUBENSTEIN, Kimberly Ann MCHALE, Stephen C. PISCITELLI
Filed: 18 Aug 22
Utility
Conjugates and Methods for Treating Liver Fibrosis
8 Dec 22
Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups.
James HEYES, Richard J. HOLLAND, Mark WOOD, Alan D. MARTIN, Christine ESAU, Margrit SCHWARZ, Xin YE, Alice Hoy Lam LI, Christopher Justin PASETKA, David CROWE, Steven TYLER
Filed: 7 Dec 20
Utility
Use of Tapinarof for the Treatment of Chronic Plaque Psoriasis
17 Nov 22
Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein.
John E. KRAUS, James Lee
Filed: 22 Jul 22
Utility
Conjugates and Methods for Treating Acromegaly
15 Sep 22
Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups.
Drew KONDRATOWICZ, James HEYES, Richard J. HOLLAND, Christine ESAU, Kevin MCCLINTOCK, Christopher Justin PASETKA, Mark WOOD, Alan D. MARTIN, Margrit SCHWARZ, David CROWE, Steven TYLER
Filed: 23 Oct 20
Utility
CorrectedUse of Tapinarof for the Treatment of Atopic Dermatitis
15 Sep 22
Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis are described herein.
John E. KRAUS, James LEE
Filed: 13 Nov 19
Utility
Remittive Effects of Tapinarof In the Treatment of Plaque Psoriasis, Atopic Dermatitis, or Radiation Dermatitis
25 Aug 22
Embodiments described herein are directed to methods for treating moderate to severe plaque psoriasis, atopic dermatitis, or radiation dermatitis in a subject comprising administering about 1.0% tapinarof in a topical composition to the affected areas of the subject once a day for an initial period of time until the plaque psoriasis, atopic dermatitis, or radiation dermatitis is clear at which time the administration is stopped, and reassessing the subject from about 3 months to about 12 months after administration is stopped to determine if further treatment is required.
David Scott RUBENSTEIN, Kimberly Ann MCHALE, Stephen C. PISCITELLI
Filed: 17 Feb 22
Utility
Cerdulatinib-containing Topical Skin Pharmaceutical Compositions and Uses Thereof
28 Jul 22
Embodiments described herein are directed to topical compositions for administering cerdulatinib or a pharmaceutically acceptable salt, hydrate or solvate thereof.
Kimberly Ann MCHALE, David Scott RUBENSTEIN
Filed: 8 Jul 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first